TABLE 2.
EPO (n = 41) | Placebo (n = 37) | Total (n = 78) | ||
---|---|---|---|---|
50% re-ep*-level | yes | 40 (98%) | 35 (95%) | 75 (96%) |
No (%) | no | 1 (2%) | 2 (4%) | 3 (4%) |
Median (days) | 10 | 10 | ||
Re-ep*-likelihood | 98% | 95% | p = 0.802 |
*re-ep, re-epithelialization.
EPO (n = 41) | Placebo (n = 37) | Total (n = 78) | ||
---|---|---|---|---|
50% re-ep*-level | yes | 40 (98%) | 35 (95%) | 75 (96%) |
No (%) | no | 1 (2%) | 2 (4%) | 3 (4%) |
Median (days) | 10 | 10 | ||
Re-ep*-likelihood | 98% | 95% | p = 0.802 |
*re-ep, re-epithelialization.